Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2016, Article ID 7938062, 4 pages
http://dx.doi.org/10.1155/2016/7938062
Case Report

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy

Department of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, Japan

Received 12 July 2016; Accepted 16 October 2016

Academic Editor: Kenneth S. Waxman

Copyright © 2016 Kenichi Nitta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Z. Goldhaber and H. Bounameaux, “Pulmonary embolism and deep vein thrombosis,” The Lancet, vol. 379, no. 9828, pp. 1835–1846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. R. Büller, H. Décousus, M. A. Grosso et al., “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 369, no. 15, pp. 1406–1415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Siegal, J. T. Curnutte, S. J. Connolly et al., “Andexanet alfa for the reversal of factor Xa inhibitor activity,” New England Journal of Medicine, vol. 373, no. 25, pp. 2413–2424, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. R. Lara and M. I. Schwarz, “Diffuse alveolar hemorrhage,” Chest, vol. 137, no. 5, pp. 1164–1171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Santalo, P. Domingo, J. Fontcuberta, M. Franco, and J. Nolla, “Diffuse pulmonary hemorrhage associated with anticoagulant therapy,” European Journal of Respiratory Disease, vol. 69, no. 2, pp. 114–119, 1986. View at Google Scholar
  6. A. Waness, T. Aldabbagh, and M. Harakati, “Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review,” BMJ Case Reports, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Uysal, E. Çevik, S. Solak, Y. A. Acar, and M. Yalimol, “A life-threatening complication of warfarin therapy in ED: diffuse alveolar hemorrhage,” The American Journal of Emergency Medicine, vol. 32, no. 6, pp. 690.e3–690.e4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Yokoi, K. Isoda, T. Kimura, and T. Adachi, “Diffuse alveolar hemorrhage associated with dabigatran,” Internal Medicine, vol. 51, no. 18, pp. 2667–2668, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. I. Gabrilovich, D. E. Buxton, D. M. Lykins, S. M. McMillen, and O. O. A. Onadeko, “Diffuse alveolar hemorrhage secondary to apixaban administration,” Chest, vol. 146, no. 3, pp. e115–e116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cuker, D. M. Siegal, M. A. Crowther, and D. A. Garcia, “Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants,” Journal of the American College of Cardiology, vol. 64, no. 11, pp. 1128–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. D. R. Rinehart, N. R. Lockhart, L. A. Hamilton, J. R. Langdon, and A. S. Rowe, “Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity,” Critical Care Medicine, vol. 43, no. 6, pp. e203–e207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Prandoni, “The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations,” Blood Transfusion, vol. 13, no. 2, pp. 178–180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Minor, K. B. Tellor, and A. L. Armbruster, “Edoxaban, a novel oral factor Xa inhibitor,” The Annals of Pharmacotherapy, vol. 49, no. 7, pp. 843–850, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. C. V. Pollack Jr., “Coagulation assessment with the new generation of oral anticoagulants,” Emergency Medicine Journal, vol. 33, no. 6, pp. 423–430, 2016. View at Publisher · View at Google Scholar
  15. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Crackowski, and G. Pernod, “Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217–224, 2012. View at Publisher · View at Google Scholar · View at Scopus